Search results
Feb 7, 2024 · Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 ...
Gilead Sciences Colombia S.A.S. Carrera 19 # 100-45. Piso 2. Bogotá D.C. Colombia. 110121. Medical Information: comedinfo@gilead.com. Gilead Sciences is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.
Discover real-time Gilead Sciences, Inc. Common Stock (GILD) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.
Science and Medicine Gilead is committed to advancing care for people around the world, by bringing forward medicines in areas of unmet medical need. At Gilead, we strive to transform and simplify care for people with life-threatening diseases around the world.
Feb 12, 2024 · FOSTER CITY, Calif. & NEWARK, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product ...
Gilead Sciences stock chart. Gilead Sciences in Fortune Rankings. Fortune 500 Global 500 Change the World World's Most Admired Companies 100 Fastest-Growing Companies.
Aug 4, 2022 · Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, cancer ...
